Revelation Biosciences Q3 loss widens to $3.32M
Revelation said its cash and cash equivalents were sufficient to fund operations into the second quarter of 2027 under current operating plans and projections.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Revelation Biosciences, Inc. reported a net loss of $3,315,513 for the three months ended September 30, 2026, compared with $1,907,176 for the same period in 2025. Net cash used for operating activities was $2.6 million versus $1.6 million. For the nine months ended September 30, 2026, net loss was $9,647,948, compared with $6,402,643 for the same period in 2025.
Cash and cash equivalents were $9,121,630 as of September 30, 2026, compared with $10,700,331 as of December 31, 2025. Based on current operating plans and projections, Revelation believes its cash and cash equivalents are sufficient to fund operations into the second quarter of 2027.
The company selected a full-service contract research organization with global operations for its upcoming study of Gemini in patients with acute kidney injury. An independent market assessment indicated a potential $94 billion total addressable market for Gemini. Revelation describes Gemini as its proprietary formulation of PHAD, a TLR4 agonist; it is evaluating Gemini for acute kidney injury and developing it for chronic kidney disease, severe-burn hyperinflammation and infection, and prevention of post-surgical infection.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Major pointThird-quarter net loss: $3,315,513 versus $1,907,176 in 2025.
- Moderate pointOperating cash use: $2.6 million versus $1.6 million in 2025.
Filing Explained
This filing’s
8-K Event Classification
Key Figures
Key Terms
total addressable market financial
phosphorylated hexaacyl disaccharide (PHAD®) technical
TLR4 agonist technical
deemed dividends financial
Earnings Snapshot
Revelation believes its current cash and cash equivalents are sufficient to fund operations into the second quarter of 2027, based on current operating plans and projections.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much cash did REVB report at September 30, 2026, and how long would it last?
What were REVB's third-quarter 2026 net loss and operating cash use?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
|||
|
|
|||
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, Revelation Biosciences, Inc. issued a press release announcing its financial results for the three and nine months ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1.
The information in Item 2.02 and in Exhibit 99.1 will not be treated as “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or into another filing under the Exchange Act, unless that filing expressly incorporates this information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
||
|
|
|
Exhibit No. |
|
Description |
99.1 |
|
Press release, dated November 5, 2026 |
104 |
|
Cover Page Interactive Data File (embedded with the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
REVELATION BIOSCIENCES, INC. |
|
|
|
Date: November 5, 2026 |
By: |
/s/ Chester S. Zygmont, III |
|
|
Chester S. Zygmont, III |
Exhibit 99.1
Revelation Biosciences, Inc. Announces Financial Results
For the Three and Nine Months Ended September 30, 2026
SAN DIEGO – November 5, 2026 – Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026.
Corporate Highlights
“The Revelation team remains focused on progressing Gemini's development for the benefit of patients,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to providing additional updates in the near term.”
Results of Operations
As of September 30, 2026, Revelation had $9.1 million in cash and cash equivalents, compared to $10.7 million as of December 31, 2025. The decrease in cash and cash equivalents was primarily due to net cash proceeds from the January 2026 warrant inducement, offset by cash used for operating activities. Based on current operating plans and projections, Revelation believes its current cash and cash equivalents are sufficient to fund operations into the second quarter of 2027.
Net cash used for operating activities for the three months ended September 30, 2026 was $2.6 million compared to net cash used for operating activities of $1.6 million for the same period in 2025. Net loss for the three months ended September 30, 2026 was $3.3 million, or $5.92 basic and diluted net loss per share compared to net loss of $1.9 million, or $49.51 basic and diluted net loss per share for the three months ended September 30, 2025. Net loss for the nine months ended September 30, 2026 was $9.6 million, or $29.37 basic and diluted net loss per share compared to net loss of $6.4 million, or $273.33 basic and diluted net loss per share for the nine months ended September 30, 2025.
About Gemini
Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two Phase 1 clinical studies. See additional details here.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment for chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth, profitability, and retain its key employees; the possibility that Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies; the timing of clinical data; the outcome of the clinical data, including whether the results of such studies are positive or whether they can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
REVELATION BIOSCIENCES, INC.
Condensed Consolidated Statements of Operations
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
1,512,898 |
|
|
$ |
922,857 |
|
|
$ |
4,808,183 |
|
|
$ |
3,099,667 |
|
General and administrative |
|
|
1,870,678 |
|
|
|
1,020,154 |
|
|
|
5,330,134 |
|
|
|
3,399,559 |
|
Total operating expenses |
|
|
3,383,576 |
|
|
|
1,943,011 |
|
|
|
10,138,317 |
|
|
|
6,499,226 |
|
Loss from operations |
|
|
(3,383,576 |
) |
|
|
(1,943,011 |
) |
|
|
(10,138,317 |
) |
|
|
(6,499,226 |
) |
Other income (expense), net: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other income (expense), net |
|
|
68,063 |
|
|
|
35,224 |
|
|
|
490,369 |
|
|
|
94,512 |
|
Change in fair value of warrant liability |
|
|
— |
|
|
|
611 |
|
|
|
— |
|
|
|
2,071 |
|
Total other income (expense), net |
|
|
68,063 |
|
|
|
35,835 |
|
|
|
490,369 |
|
|
|
96,583 |
|
Net loss |
|
$ |
(3,315,513 |
) |
|
$ |
(1,907,176 |
) |
|
$ |
(9,647,948 |
) |
|
$ |
(6,402,643 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deemed dividends |
|
|
— |
|
|
|
(2,769,742 |
) |
|
|
(5,681,616 |
) |
|
|
(5,951,528 |
) |
Net loss attributable to common stockholders |
|
|
(3,315,513 |
) |
|
|
(4,676,918 |
) |
|
|
(15,329,564 |
) |
|
|
(12,354,171 |
) |
Net loss per share, basic and diluted |
|
$ |
(5.92 |
) |
|
$ |
(49.51 |
) |
|
$ |
(29.37 |
) |
|
$ |
(273.33 |
) |
Weighted-average shares used to compute net loss per share, basic and diluted |
|
|
559,596 |
|
|
|
94,455 |
|
|
|
522,028 |
|
|
|
45,199 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
REVELATION BIOSCIENCES, INC.
Condensed Consolidated Balance Sheets
|
|
September 30, |
|
|
December 31, |
|
||
ASSETS |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
9,121,630 |
|
|
$ |
10,700,331 |
|
Prepaid expenses and other current assets |
|
|
146,516 |
|
|
|
111,297 |
|
Total current assets |
|
|
9,268,146 |
|
|
|
10,811,628 |
|
Property and equipment, net |
|
|
163,847 |
|
|
|
18,067 |
|
Operating lease right-of-use asset |
|
|
559,163 |
|
|
|
722,288 |
|
Other assets |
|
|
30,941 |
|
|
|
30,941 |
|
Total assets |
|
$ |
10,022,097 |
|
|
$ |
11,582,924 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
1,066,836 |
|
|
$ |
577,501 |
|
Accrued expenses |
|
|
916,160 |
|
|
|
1,397,644 |
|
Operating lease liability |
|
|
344,588 |
|
|
|
23,013 |
|
Total current liabilities |
|
|
2,327,584 |
|
|
|
1,998,158 |
|
Operating lease liability, net of current portion |
|
|
460,811 |
|
|
|
723,771 |
|
Total liabilities |
|
|
2,788,395 |
|
|
|
2,721,929 |
|
Commitments and Contingencies |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Common Stock, $0.001 par value; 500,000,000 shares authorized; 683,442 and 226,330 issued and outstanding at September 30, 2026 and December 31, 2025, respectively |
|
|
683 |
|
|
|
226 |
|
Additional paid-in-capital |
|
|
66,300,254 |
|
|
|
58,280,056 |
|
Accumulated deficit |
|
|
(59,067,235 |
) |
|
|
(49,419,287 |
) |
Total stockholders’ equity |
|
|
7,233,702 |
|
|
|
8,860,995 |
|
Total liabilities and stockholders’ equity |
|
$ |
10,022,097 |
|
|
$ |
11,582,924 |
|
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose, Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences, Inc.
Email: czygmont@revbiosciences.com